The Medical Letter on Drugs and Therapeutics
June 29, 2009
Subscribers: Log in to read full issue. Not a subscriber? Subscribe or purchase issue.
In Brief: Biennial IV Zoledronic Acid (Reclast) for Prevention of Osteoporosis
June 29, 2009 (Issue: 1315)The FDA, which had previously approved intravenous (IV) administration of 5 mg of zoledronic acid (Reclast – Novartis) once a year for treatment of postmenopausal osteoporosis (Med Lett Drugs Ther 2007; 49:89), has now approved the same dose for...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.